Health Care/Hospital
Ribbon of Hope: A Collaborative Cancer Support Initiative by BIG Pharmacy and CARiNG Pharmacy
JOHOR BAHRU, Malaysia, Oct. 25, 2024 /PRNewswire/ -- BIG CARiNG Group proudly announces the unveiling of its revolutionary Cancer Support Program, namely "Ribbon of Hope" for you and those you care for at the Biggest Health & Beauty Expo held at Mid Valley Southkey. This initiative is designed to...
TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability
NANJING, China, Oct. 25, 2024 /PRNewswire/ -- On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by Professor Wang Yongjun from Beijing Tiantan Hospital, was published in an oral report at the 16th World Stroke Conference (WSC): brain cell protection combined with edaravone ...
HiConf Seoul 2024 successfully wraps up, sparks up discussions for future of food tech and international partnerships
* Global food tech experts gathered to share innovative ideas, discuss market insights, and explore development potential * Abu Dhabi-based investment firm HITI partners with Dongwha Pharmaceutical to manufacture and distribute cognitive enhancement ingredients in theMiddle East * HITI join...
Everest Medicines Announces the Launch of VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area, Offering a New Option for Moderately to Severely Active Ulcerative Colitis Patients
SHANGHAI, Oct. 25, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that, through the "Hong Kong and Ma...
Volpara Health Surpasses 300 Peer-Reviewed Papers
Milestone reinforces readership in AI-powered breast cancer detection WELLINGTON, New Zealand, Oct. 25, 2024 /PRNewswire/ -- Volpara Health, a Lunit company and global leader in artificial intelligence (AI)-powered breast health solutions, has reached a significant milestone: the publication ...
Shaklee, A Leader in Clean Wellness and Skincare, Expands into Australia
The Brand Ushers in a New Era of Growth as It Approaches Its 75th Anniversary MIAMI, Oct. 24, 2024 /PRNewswire/ -- Shaklee, a leading health and wellness company, whose founder invented the first multivitamin in the U.S., is launching in its newest international market:Australia. The news comes a...
Frost & Sullivan Honors Industry Leaders with Prestigious 2024 Best Practices Awards
Top Innovators Recognized for Outstanding Achievements at Semiannual Awards Gala SAN ANTONIO, Oct. 24, 2024 /PRNewswire/ -- The 2024 Frost & Sullivan Best Practices Awards Gala, hosted at the JW Marriott Tucson Starr Pass Resort in Tucson, AZ, brought together the best in business to celebrate tra...
EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs
PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announce today that they have been awarded a two-year,$2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug Administration (FDA) to develop standardized co...
IMG Announces 2024 Leave Your Mark Grant Winners
INDIANAPOLIS, Oct. 24, 2024 /PRNewswire/ -- IMG (International Medical Group), an award-winning global insurance benefits and assistance services company, is excited to announce the winners of its eighth annual Leave Your Mark Grant. This year, more than 800 organizations and individuals submitte...
Innovation at the Forefront: Angel Yeast Shines at FHA 2024
SINGAPORE, Oct. 24, 2024 /PRNewswire/ -- The FHA 2024 exhibition in Singapore,
Asia's largest food and beverage show, is taking place from October 22 to 25,
and is generating significant buzz within the hospitality sector. Angel Yeast
Besmile Announces RMB 1 Million Donation to Support Shanghai 9th People's Hospital's Dental Service Development
SHANGHAI, Oct. 24, 2024 /PRNewswire/ -- Dental service provider Besmile proudly announces a donation ofRMB 1 million to Shanghai 9th People's Hospital, reinforcing its commitment to enhancing dental service capabilities within the industry. The fund will help elevate the medical facilities to cre...
Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction
* Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing overUS$100B per year * Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeutics * Promising efficacy ...
SeekIn Presents Cost-Effective Two-Step Multi-Cancer Screening Strategy and Breakthrough Lung Cancer Early Detection Test at Early Detection of Cancer Conference in San Francisco
SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, announced today its innovative two-step multi-cancer screening strategy at the Early Detection of Cancer Conference in San Francisco. This approach is designed to signifi...
Global Biopharma Thought Leaders Gather in London: Join the 2024 GenScript Biotech Global Forum for Cutting-Edge Insights
PISCATAWAY, N.J., Oct. 24, 2024 /PRNewswire/ -- Cell therapy, gene therapy, and mRNA vaccines are revolutionizing healthcare, offering innovative treatments for a wide range of diseases. However, as these therapies progress, they encounter challenges like safety assessments, cost control, and te...
Botanee & Winona Shines at COSMETIC 360: VOGUE FRANCE, Le Figaro Highlight its Award-Winning Innovations
PARIS, Oct. 24, 2024 /PRNewswire/ -- Winona, a leading cosmeceutical brand in China owned by the Botanee Group, is making its mark on the international stage with groundbreaking plant-based innovations in beauty. Its innovative approach has just earned recognition at COSMETIC 360, the world's lea...
The 2024 Seminar on International Communication of Chinese Medicine and Yi Medicine Big Health Industry Development Promotion Conference Held in Chuxiong, Yunnan Province
CHUXIONG, China, Oct. 24, 2024 /PRNewswire/ -- The 2024 Seminar on International Communication of Chinese Medicine and Yi Medicine Big Health Industry Development Promotion Conference was held in Chuxiong,Yunnan Province onOctober 21. The event was co-sponsored by the China Association of Chinese...
Pierre Fabre announce 1st Patient Dosed in Phase I/II of PFL-002/VERT-002, a targeted therapy in NSCLC with MET Alterations
Pierre Fabre Laboratories Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-002/VERT-002, an Innovative Targeted Therapy Intended to Treat Non-Small Cell Lung Cancer with MET Alterations PFL-002/VERT-002 is a monoclonal antibody with a novel and differentiated mechanism of action,...
Founder of Hua Medicine Dr. Li CHEN was awarded the "C.C. Tan Life Science Industrialization Award"
SHANGHAI, Oct. 24, 2024 /PRNewswire/ -- The 17th "C.C. Tan Life Science Award" ceremony was held inShenyang, China, on October 9th. Dr. Li CHEN, Founder and Chief Executive Officer of Hua Medicine, was awarded the "C.C. Tan Life Science Industrialization Award". C.C. Tan Life Science Award has th...
J INTS BIO Presents Interim Findings from Phase 1/2 Clinical Trial of 4th-Generation EGFR-TKI 'JIN-A02' in NSCLC: A Potential Breakthrough in Overcoming Acquired Resistance to Targeted Therapy
SEOUL, South Korea, Oct. 24, 2024 /PRNewswire/ -- J INTS BIO, a pioneering biopharmaceutical company, has unveiled promising interim results from the Phase 1/2 clinical trial of its novel 4th-generation EGFR Tyrosine Kinase Inhibitor (TKI), JIN-A02, aimed at EGFR-mutated non-small cell lung cance...
J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance
SEOUL, South Korea, Oct. 23, 2024 /PRNewswire/ -- J INTS BIO, a leader in oncology drug development, has revealed interim preclinical results of its second-generation synthetic HSP90 inhibitor, JIN-001, at the ENA (EORTC-NCI-AACR) Symposium held inBarcelona, Spain, from October 23-25, 2024. The ...
Week's Top Stories
Most Reposted
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
[Picked up by 323 media titles]
2025-01-13 09:05RuggON Launches VIKING II: Transforming Fleet Management with Unmatched Technology and Flexibility
[Picked up by 295 media titles]
2025-01-14 21:00URBAN REVIVO Celebrates Lunar New Year with Unique Collaboration with Artist Mercedes Bellido
[Picked up by 294 media titles]
2025-01-13 10:44Gen Z Travelers Drive Buy Now, Plan Later Travel Bookings by Over 20%: Fliggy's 2024 Buy Now Plan Later Travel Insight
[Picked up by 286 media titles]
2025-01-10 16:04LANDI Global Unveils Flagship Cx20: Elevating business efficiency and customer experience with a next-generation Windows-powered terminal
[Picked up by 274 media titles]
2025-01-11 22:30